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Background
To assess the cumulative and allergen-specific magnitude
of effect, and its relative clinical impact, of sublingual
allergy immunotherapy with carbamylated monomeric
allergoids for allergic rhinoconjunctivitis. Carbamylated
allergoids are hypoallergenic extracts with enhanced bioa-
vailability, consequent to a partial resistance to enzymatic
degradation, providing efficient dose-tuning.
Methods
Literature was searched for double-blind placebo-con-
trolled randomized trials administering this treatment,
without any restrictions. Pooled analysis of the effects
on total symptoms scores (TSSs) during the first season
of treatment was performed and for each selected trial
the relative clinical impact (RCI) was calculated as the
percentage reduction in TSSs obtained with active treat-
ment compared to placebo. The effect size (SMD), the
overall and allergen-related RCI were used to estimate
an indirect comparison with pharmacotherapy (based on
summary data recently extracted from literature).
Results
Eight studies (4 in grass, 2 in mites, 1 in pellitory, 1 in
ragweed allergy) met inclusion criteria and were pooled,
comparing overall 180 patients treated with active and
155 with placebo. The overall SMD for TSSs resulted
[-0.99 (IC -1.41 to -0.57) p<0.001] with a significant
interstudy heterogeneity (I2 = 68%). SMD for grass pol-
len tablets was [-0.58 (IC -0.89 to -0.27) p<0.001], for
mite tablets was [-1.54 (IC -2.07 to -1.02) p<0.001]. The
weighted mean RCI was overall -31.69%, for grass pollen
tablets -32.14%, for mite tablets -24.27%.
Conclusions
Indirectly compared to the relative clinical impact of
standard pharmacotherapy (antihistamines RCI: -15.0%;
antileukotrienes RCI: -6.5%; nasal corticosteroids RCI:
-23.5%), carbamylated monomeric allergoids result
highly effective in providing symptoms relief in seasonal
and perennial allergic rhinoconjunctivitis. This estima-
tion is most likely conservative and apparently reduced
by the numerous methodological aspects that differenti-
ate clinical trials on drugs and allergen immunotherapy.
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